BioSpace News Archive

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, has completed dosing of SBI-100 Ophthalmic Emulsion (“OE”) in the first cohort of healthy participants in the single ascending dose (“SAD”) part of its Phase 1 study being conducted by CMAX Clinical Research in Adelaide, Australia.

The global biotechnology market size was exhibited at USD 859.94 billion in 2022 and it is expected to hold around USD 1,683.52 billion by 2030, growing at a CAGR of 8.7% from 2022 to 2030.

Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the third quarter of fiscal year 2023 at approximately 8:00 A.M. Eastern time on Monday, February 6, 2023.

Agilent Technologies Inc. announced that CEO Mike McMullen and CFO Bob McMahon will present at the Goldman Sachs Healthcare CEOs Unscripted Conference and the J.P. Morgan Healthcare Conference.